Search results
Showing 601 to 650 of 8174 results
How 'surrogate outcomes' influence long-term health outcomes
NICE working with international organisations to develop guidance
Evidence-based recommendations on AposHealth for knee osteoarthritis.
View recommendations for MTG76Show all sections
NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after a previous anti-HER2-based regimen in adults. This is because Daiichi Sankyo UK did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA879
Ground-breaking commercial deals for anti-cancer medicine olaparib have paved the way for hundreds to benefit in final draft guidance published today (6 April 2023) by NICE that recommends it for some types of early breast cancer and advanced prostate cancer.
Percutaneous thoracic duct embolisation for persistent chyle leak (IPG755)
Evidence-based recommendations on percutaneous thoracic duct embolisation for persistent chyle leak. In this procedure, under general anaesthesia, ultrasound and X-rays are used to create an image of the thoracic duct and find the leak. Then, using a needle, a tube is inserted through the abdominal wall (percutaneous) and guided into the thoracic duct. Small metal coils and medical glue are inserted through the tube and used to plug the leak (embolisation). The aim is to stop the leak.
View recommendations for IPG755Show all sections
Focal therapy using high-intensity focused ultrasound for localised prostate cancer (IPG756)
Evidence-based recommendations on focal therapy using high-intensity focused ultrasound for localised prostate cancer. This involves using high-intensity focused ultrasound to heat up and destroy only the areas of the prostate with cancer (focal therapy). The aim is to destroy the cancer while reducing damage to healthy prostate tissue.
View recommendations for IPG756Show all sections
Maximal cytoreductive surgery for advanced ovarian cancer (IPG757)
Evidence-based recommendations on maximal cytoreductive surgery for advanced ovarian cancer. This involves removing all or almost all visible cancerous tissue. More tissue is removed than with standard surgery. The aim is to improve outcomes for people with advanced ovarian cancer.
View recommendations for IPG757Show all sections
Radiofrequency ablation for palliation of painful spinal metastases (IPG758)
Evidence-based recommendations on radiofrequency ablation for palliation of painful spinal metastases. This involves inserting a needle-like probe containing an electrode into the spinal metastases. This produces an electrical current that aims to relieve pain and other symptoms.
View recommendations for IPG758Show all sections
Evidence-based recommendations on radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastases. This involves inserting a needle-like probe containing an electrode into the spinal metastases. This produces an electrical current that aims to relieve pain and other symptoms.
View recommendations for IPG759Show all sections
UrgoStart for treating diabetic foot ulcers and leg ulcers (MTG42)
Evidence-based recommendations on UrgoStart for treating diabetic foot ulcers and leg ulcers.
How my experience as a patient helped shape NICE guidelines for colorectal cancer
Following my surgery and treatment for colorectal cancer in 2014, I wanted to contribute to research in the cancer field and hopefully improve things for patients in the future, so I applied and was accepted to be a lay member for NICE’s colorectal cancer guideline committee.
Research to access pathway for investigational drugs for COVID-19 (RAPID C-19)
A multi-agency collaboration to get treatments for COVID-19 to patients quickly
The latest gender pay gap data from NICE
NICE recommends genetic test to prevent newborn babies going deaf
A genetic test to establish if a newborn baby is vulnerable to deafness if treated with a commonly used antibiotic has been recommended by NICE in final guidance.
Working at the forefront of neurodegenerative disease research
Claire Hawksworth reveals NICE’s role in a global partnership to better understand neurodegenerative conditions and speed up delivery of innovative treatments.
Hundreds of people with cervical cancer are set to receive the first immunotherapy drug for an advanced form of the disease as NICE publishes final draft guidance today (Wednesday 29 March 2023) recommending its use in the Cancer Drugs Fund (CDF).
Macimorelin for diagnosing growth hormone deficiency (MIB320)
NICE has developed a medtech innovation briefing (MIB) on macimorelin for diagnosing growth hormone deficiency .
The first and currently only gene therapy for children with an ultra-rare genetic disorder has been recommended by NICE in final draft guidance published today (23 March 2023).
NICE identifies improvements for people with acute kidney injury in updated quality standard
An updated quality standard published today (23 March 2023) by NICE outlines improvements in care for people who have or are at risk of acute kidney injury.
Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)
Evidence-based recommendations on finerenone (Kerendia) for stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults.
This quality standard covers preventing, detecting and managing acute kidney injury in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS76Show all sections
Sections for QS76
- Quality statements
- Quality statement 1: Raising awareness in people at risk
- Quality statement 2: Identifying acute kidney injury in people admitted to hospital
- Quality statement 3: Response to acute kidney injury warning stage 2 test result
- Quality statement 4: Response to acute kidney injury warning stage 3 test result
- Quality statement 5: Referral for renal replacement therapy
- Quality statement 6: Clinical review after hospital discharge
- Update information
Evidence-based recommendations on nivolumab (Opdivo) with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer in adults.
Four innovative tests for diagnosing UTIs could help in the fight against antimicrobial resistance
Innovative tests with the potential to help people with a urinary tract infection (UTI) receive the correct course of antibiotics more quickly could soon be considered for use in the NHS.
Agenda and papers of the NICE public board meeting on 22 March 2023
BPMpathway for rehabilitation support in joint replacement surgery (MIB319)
MIB319 BPMpathway for rehabilitation support in joint replacement surgery has been withdrawn. This is because factual inaccuracies have been identified. NHS England no longer fund NICE to produce or maintain medtech innovation briefings, therefore these are no longer being reviewed.
Guidance Executive
There are a number of ways you can get involved in the development of our guidance.
The percentage of patients with a BMI of 27.5 kg/m2 or more (or 30 kg/m2 or more if ethnicity is recorded as White) in the preceding 12 months who...
Early value assessment (EVA) guidance on CaRi-Heart for predicting cardiac risk in suspected coronary artery disease....
Recommendation ID IPG752/01 Question Evidence on the safety and efficacy of biodegradable spacer insertion to reduce rectal toxicity during
Recommendation ID NG231/04A Question Endoscopic treatments: For adults with Barrett's oesophagus with dysplasia, what is the effectiveness
Recommendation ID NG231/04B Question Endoscopic treatments: For adults with stage 1 oesophageal adenocarcinoma, what is the effectiveness
Recommendation ID IPG751/01 Question Evidence on the safety and efficacy of transvenous obliteration of gastric varices is adequate in
Recommendation ID NG231/03 Question Oesophagectomy: What is the effectiveness of endoscopic resection with or without adjuvant chemoradiotherapy
Recommendation ID NG231/01 Question Diagnostic accuracy of endoscopic surveillance: What is the diagnostic accuracy of different endoscopic
Recommendation ID NG231/05A Question Frequency and duration of endoscopic follow-up: What is the optimal frequency and duration of endoscopic
Recommendation ID NG231/05B Question Frequency and duration of endoscopic follow-up: What is the optimal frequency and duration of endoscopic
Recommendation ID NG231/02 Question Frequency and duration of endoscopic surveillance: What is the usefulness of clinical and molecular
NICE recommended weight-loss drug to be made available in specialist NHS services
Thousands of people will soon be able to be prescribed a drug to help them lose weight as part of their treatment in an NHS specialist weight management service.
QbTest for the assessment of attention deficit hyperactivity disorder (ADHD) (MIB318)
NICE has developed a medtech innovation briefing (MIB) on QbTest for the assessment of attention deficit hyperactivity disorder (ADHD) .
Recommendation ID DG51/03 Question How frequently the remote monitoring devices were modelled as being used substantially affected the
Recommendation ID DG51/01 Question There is uncertainty about how much remote monitoring devices would affect resource use in the NHS and
Recommendation ID DG51/02 Question How much using remote monitoring devices to guide decisions about care affects symptoms, and therefore
Healthcare professionals - shaping our work A wide range of healthcare professionals, including primary care colleagues, work with NICE to develop our
This quality standard covers prevention of type 2 diabetes in adults (aged 18 and over) and care and treatment for adults with type 2 diabetes. It describes high-quality care in priority areas for improvement.
View quality statements for QS209Show all sections
Sections for QS209
- Quality statements
- Quality statement 1: Preventing type 2 diabetes
- Quality statement 2: Structured education programme
- Quality statement 3: Continuous glucose monitoring for adults on multiple daily insulin injections who cannot self-monitor using capillary blood glucose monitoring
- Quality statement 4: Continuous glucose monitoring for adults who use insulin and need help monitoring their blood glucose
- Quality statement 5: Treatment with an SGLT2 inhibitor
- Quality statement 6: 9 key care processes
- Quality statement 7: Assessing the risk of diabetic foot problems on admission to hospital
This quality standard covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It describes high-quality care in priority areas for improvement.
View quality statements for QS208Show all sections
Sections for QS208
- Quality statements
- Quality statement 1: Structured education programmes
- Quality statement 2: Continuous glucose monitoring
- Quality statement 3: Statin therapy for primary prevention of cardiovascular disease
- Quality statement 4: 9 key care processes
- Quality statement 5: Assessing the risk of diabetic foot problems on admission to hospital
- Quality statement 6: Support to self-manage diabetes during inpatient admissions
- Quality statement 7 (placeholder): Identification of eating disorders in adults with type 1 diabetes
Eight digital enabled therapies to treat depression and anxiety disorders in adults have been conditionally recommended by NICE in draft guidance issued today (Wednesday 1 March 2023).
How the health and care system uses our recommendations to improve outcomes in priority areas.
Asfotase alfa for treating paediatric-onset hypophosphatasia (HST23)
Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in babies, children, young people and adults.
Endoluminal gastroplication for gastro-oesophageal reflux disease (IPG753)
Evidence-based recommendations on endoluminal gastroplication for gastro-oesophageal reflux disease. This involves an endoscopic fastening device being inserted through the mouth and into the stomach, along with an endoscope for constant visualisation. The device is used to attach the fundus to the anterior and left lateral wall of the distal oesophagus slightly above the oesophagogastric junction.
View recommendations for IPG753Show all sections